Vascular endothelial cell growth inhibitor, VEGI-192a

• US 7,750,133 B2
• Filed: 12/06/2007
• Issued: 07/06/2010
• Est. Priority Date: 11/09/2001
• Status: Expired due to Fees

• Current Assignee: Georgetown University
• Original Assignee: Georgetown University
• Inventors: Pan, Hongguang, Li, Luyuan
• Primary Examiner(s): Reddig; Peter J
• Application Number:
  US11/999,918
• Publication Number:
  US 20090227014A1
• Time in Patent Office: 943 Days
• Field of Search: None
• US Class Current: 536/23.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/70575 NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 NGF C07K14/48, TNF C07K14/525
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

This invention discloses two new VEGI isoforms named VEGI-_192a and VEGI-_192b consisting of 192 amino acid residues. These isoforms show endothelial cell-specific expression and share a C-terminal 151-residues segment with the previously described VEGI-₁₇₄ and VEGI-₂₅₁. Methods of using these isoforms of VEGI in diagnosing, screening agonist and antagonist of the isoforms, and treating various angiogenesis-related diseases are also disclosed.

Claims

1. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide sequence of SEQ ID NO:

4.

2. The polynucleotide of claim 1, wherein said polynucleotide further comprises a detectable label.

3. The polynucleotide of claim 1, wherein said polynucleotide is immobilized on a surface.

4. The polynucleotide of claim 1, wherein said polynucleotide consists of a nucleotide sequence encoding the polypeptide sequence of SEQ ID NO:

4.

5. The polynucleotide of claim 1, wherein said polynucleotide encodes a fusion protein comprising the polypeptide sequence of SEQ ID NO:

4 fused to another polypeptide.

6. The polynucleotide of claim 1, wherein said nucleotide sequence comprises the nucleic acid sequence of SEQ ID NO:

1.

7. The polynucleotide of claim 1, wherein said polynucleotide encodes a polypeptide having a biological activity of anti-angiogenesis.

8. A vector comprising the polynucleotide of claim 1.

9. The vector of claim 1, wherein said vector is an expression vector.

10. A host cell in a cell culture, said host cell comprising the vector of claim 8.

11. A composition comprising the polynucleotide of claim 1.